ReviewNatural product reports2026
Expanding bile acid diversity
Review in Natural product reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Covering: 2019 to April 2026Bile acids, originally identified as digestive emulsifiers, are now recognized as signaling molecules at the nexus of metabolism and immunity. Recent advances in metabolomics have revealed unexpected chemical diversity of BAs, derived from previously unrecognized conjugation pathways involving both the gut microbiota and the host. This includes microbial conjugation of the bile acid carboxy terminus with diverse amino acids and other biogenic amines as well as host-derived conjugation with cysteamine derivatives. In addition, microbial acylation of the steroid core has been shown to introduce succinyl, acetyl, and other chemical modifications, including expansion of the canonical bile acid carbon skeleton. This review synthesizes recent discoveries (2019-2026) in bile acid conjugation chemistry and highlights how the expanded bile acid diversity regulates host physiology through activation of different nuclear receptors and G-protein coupled receptors, including therapeutic implications for metabolic and immune disorders such as non-alcoholic steatohepatitis, inflammatory bowel disease, and cardiometabolic diseases. The emerging picture reveals that bile acid pools result from an intricate network of host-microbe metabolic pathways, and that considering both host and microbial contributions is essential for understanding bile acid biology in health and disease.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.